Hikma launches prefilled syringe capability with heparin sodium injection
Hikma is introducing its prefilled syringe capability in the United States. The company is debuting the prefilled syringes with heparin sodium injection.
“Medical professionals are always in need of tools that help them improve the speed, safety and accuracy of patient care and that is why Hikma is excited to launch our prefilled syringe capability,” said Dan Motto, Hikma’s executive vice president of commercial and business development, U.S. injectables, adding, “Our heparin sodium injection prefilled syringes are ready-to-administer and will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily and with reduced risk. This is another example of how Hikma is using its capabilities as a leading generic pharmaceutical company to serve the growing needs of U.S. medical professionals and their patients.”
“Hikma is continuously expanding its broad and deep portfolio of essential injectable medicines” said Riad Mishlawi, Hikma injectables president. “We have made significant investments in our U.S. manufacturing capabilities to bring this new prefilled syringe capability to market, and Heparin is the first of many important medicines we will deliver in this form.”
Heparin sodium injection is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism; prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism; and anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.
“Medical professionals are always in need of tools that help them improve the speed, safety and accuracy of patient care and that is why Hikma is excited to launch our prefilled syringe capability,” said Dan Motto, Hikma’s executive vice president of commercial and business development, U.S. injectables, adding, “Our heparin sodium injection prefilled syringes are ready-to-administer and will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily and with reduced risk. This is another example of how Hikma is using its capabilities as a leading generic pharmaceutical company to serve the growing needs of U.S. medical professionals and their patients.”
“Hikma is continuously expanding its broad and deep portfolio of essential injectable medicines” said Riad Mishlawi, Hikma injectables president. “We have made significant investments in our U.S. manufacturing capabilities to bring this new prefilled syringe capability to market, and Heparin is the first of many important medicines we will deliver in this form.”
Heparin sodium injection is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism; prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism; and anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.